Nexalin Tech

Q2 FY2026 EarningsQ2 FY26 missed consensus estimates significantly on the top line, with revenue of $12,161 vs. $90,000 expected, representing an 83% YoY decline due to a sharp drop in international equipment sales. While gross margin of 75.0% exceeded the 78.0% expectation slightly in direction (though lower in absolute terms compared to consensus at 78.0%), the operating loss widened to $2.25M vs. an expected $2.00M. The company faces a Nasdaq delisting determination and reported substantial doubt regarding its ability to continue as a going concern, despite advancing its Gen-3 HALO clinical trials.